Latest Curvebeam Ai (Asx:Cvb) News

CurveBeam AI reports a 33% increase in Q1 FY26 purchase orders, secures A$6.5 million in new funding, and finalizes a strategic joint venture for China distribution and manufacturing rights.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.

CurveBeam AI has inked a decade-long exclusive partnership with a major Chinese medical device joint venture, unlocking rapid market entry and a $10 million capital boost to expand its weight bearing CT and AI solutions across Greater China.

CurveBeam AI has received $5.6 million of its $6.5 million placement, issuing shares for the settled tranche while awaiting the remaining offshore transfer. The company plans to complete the share issuance once the final funds arrive.

CurveBeam AI Limited has secured A$6.5 million in new capital to fuel global growth of its HiRise™ weight-bearing CT scanner, deepen its partnership with orthopaedic giant Stryker, and advance a potential strategic deal in China.

CurveBeam AI has secured A$6.5 million through an institutional placement and completed a €10 million vendor financing facility to accelerate sales of its HiRise™ CT scanner. The company is also progressing a strategic partnership in China and advancing surgical robot validation.

CurveBeam AI Limited reported a striking 86% revenue increase to $12.1 million in FY25, alongside a 27% reduction in net loss, signaling improving financial health despite ongoing challenges with its HiRise device validation.

CurveBeam AI Limited posted a strong 85% increase in revenue to $12.1 million for FY25, alongside a reduced net loss of $16.8 million. Despite operational improvements and a recent $11.58 million capital raise, the company flags material uncertainty over its ability to continue as a going concern.

CurveBeam AI reported a solid 18% increase in purchase orders for FY25, alongside record cash receipts and positive operational cash flow in Q4. The company is also advancing a significant vendor financing facility to support growth in key markets.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage and emissions reduction targets.

CurveBeam AI reported a robust 40% increase in purchase orders during Q3 FY25 and secured a non-binding A$18 million vendor financing term sheet, positioning the company for cashflow positivity in Q4.

CurveBeam AI Limited reported a $4.367 million net operating cash outflow for Q3 2025 but anticipates a significant improvement in cash flow driven by device installations and customer receipts, with no immediate plans for capital raising.